Stock Rich List
#530 on the corporate holders of 813 holders

Third Rock Ventures V, L.P.

Director at Rapport Therapeutics.

$154M
in disclosed stock, +$1.2M (+0.81%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
530th of 813
Companies held
1
Largest holding
RAPP, 100.0% of total
Latest SEC filing
Oct 30, 2026
Listed but not counted
$73.8M

What the $154M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Rapport Therapeutics RAPP
Common Stock
Directly6,518,620$23.59$154M100.0%Form 4, Oct 30, 2026

Share counts are the amounts Third Rock Ventures V, L.P. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Third Rock Ventures V, L.P.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Rapport Therapeutics RAPP
Common Stock
Through Third Rock Ventures VI, L.P.
Held by a company or fund the insider manages
2,159,694$23.59$50.9M—Form 4, Oct 30, 2026
Rapport Therapeutics RAPP
Common Stock
Through Third Rock Ventures VI, L.P.
Held by a company or fund the insider manages
969,218$23.59$22.9M—Form 4, May 26, 2026

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
May 26, 2026SoldRAPP18,572$40.05$744KView
May 11, 2026SoldRAPP133,618$40.24$5.4MView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
527ALS Invest 1 B.V.
10% owner, Amylyx Pharmaceuticals
$154M−$2.5M (−1.58%)
528Boxer Capital Management, LLC
Insider, Tango Therapeutics
$154M+$5.6M (+3.75%)
529Yorktown Energy Partners IX, L.P.
10% owner, Riley Exploration Permian
$154M−$637K (−0.41%)
530Third Rock Ventures V, L.P.
Director, Rapport Therapeutics
$154M+$1.2M (+0.81%)
531New Enterprise Associates 14, L.P.
10% owner, Enliven Therapeutics
$153M+$5.0M (+3.39%)
532Mpm Asset Management LLC
10% owner, Aktis Oncology
$153M+$2.4M (+1.58%)
533RC IV Cayman ICW Equity LLC
Insider, Driven Brands Holdings
$152M−$2.1M (−1.37%)

Other Rapport Therapeutics insiders

All RAPP insiders

Questions

How much stock does Third Rock Ventures V, L.P. own?

Third Rock Ventures V, L.P. holds $153,774,246 in listed stock based on SEC filings and current prices, mostly Rapport Therapeutics (RAPP). That ranks 530th on the Stock Rich List.

Is this Third Rock Ventures V, L.P.'s net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Third Rock Ventures V, L.P. last buy or sell stock?

The most recent open-market trade on file is a sale of 18,572 RAPP shares on May 26, 2026 at $40.05.